Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

What is the WIN Consortium?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.04.17
Views: 2182

Dr John Mendelsohn - Chairman of the WIN Consortium

Dr Mendelsohn speaks with ecancer at AACR 2017 about the aims of the WIN Consortium.

He introduces the rationale of the annual conference, with key speakers on the latest in personalised therapy coming from around the world to discuss current practice and next steps.

Dr Mendelsohn highlights the theme of this years conference as bringing the latest understandings of biomarkers and personalised care to clinical readiness, and encourages ongoing efforts in refining approaches and delivery of care.

He highlights greater understanding of cell death pathways as offering novel opportunities in understanding diseases and therapies, and ongoing research into personalised therapy for varying populations.

For more about the WIN consortium click here, or watch interviews from last year's symposium here.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation